Endovascular Engineering (E2), which specialises in the advancement of clot removal technologies for venous thromboembolism (VTE), has named Dan Rose as chief executive officer (CEO). Former CEO and founding team member Mike Rosenthal will continue as chief operating officer and remain on the company’s board of directors. He will also continue in his role as founder and general partner at Inventure Group, where E2 was incubated.
Most recently, Rose served as CEO of LimFlow, a company dedicated to limb salvage for patients with chronic limb-threatening ischemia (CLTI). He joined LimFlow as the first employee and successfully guided the company through its acquisition by Inari Medical. A press release reports that Rose assembled a “world-class” team that developed and commercialised a “practice-changing” therapy for the treatment of late-stage CLTI, which resulted in a US Food and Drug Administration (FDA) approval and a publication in the New England Journal of Medicine.
Previously, Rose served as vice president and general manager Europe for Direct Flow Medical, and led commercial and clinical activities at Sequana Medical. Earlier in his career, he held successive commercial leadership roles at Medtronic in Europe. Rose has a BA and MA from the University of Virginia (Charlottesville, USA) and an MBA from its Darden School of Business.
“Endovascular Engineering continues to set the standard in clinical innovation and patient care, driven by the steadfast dedication of our team and the invaluable support of our clinical partners,” said Rosenthal. “I am excited to see this exceptional team reach new heights under Dan’s expert leadership through the next phase of transformative growth.”
“Under Mike’s leadership, the team has achieved remarkable milestones, positioning E2 to successfully complete its ENGULF pivotal trial and advance towards 510(k) clearance from the FDA,” said Rose. “I am deeply honoured to lead this talented team with the mission of establishing the Hēlo PE thrombectomy system as the preferred option for pulmonary embolism (PE) treatment.”
